Neurocrine Biosciences

Neurocrine Biosciences NBIX Stock

$150.57   -3.844428%
Add to favorites
Market Cap
$15.24B
LOW - HIGH [24H]
$150.24 - $158.25
VOLUME [24H]
$1.59M
P/E Ratio
22.33
Earnings per share
$6.74
ISIN
US64125C1099
Price   Prediction

Neurocrine Biosciences Price Chart

Sorry, that's all we've gotfor now...

Neurocrine Biosciences (NBIX) stock price today is 150.57 USD on Tech Market Large (-3.84% on the day). Updated .

Neurocrine Biosciences NBIX Financial and Trading Overview

Neurocrine Biosciences stock price 150.57 USD
Previous Close 156.59 USD
Open 156.27 USD
Bid 144.03 USD x 200
Ask 170.52 USD x 200
Day's Range 150.24 - 158.26 USD
52 Week Range 122.14 - 186.12 USD
Volume 1.59M USD
Avg. Volume 1.33M USD
Market Cap 15.24B USD
Beta (5Y Monthly) 0.329
PE Ratio (TTM) 22.339764
EPS (TTM) 6.74 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date December 29, 1995
1y Target Est 208.54 USD

NBIX Valuation Measures

Enterprise Value 15.56B USD
Trailing P/E 22.339764
Forward P/E 12.242499
PEG Ratio (5 yr expected) 0.31
Price/Sales (ttm) 4.11716
Price/Book (mrq) 3.932461
Enterprise Value/Revenue 4.204
Enterprise Value/EBITDA 14.558

Trading Information

Neurocrine Biosciences Stock Price History

Beta (5Y Monthly) 0.329
52-Week Change 10.40%
S&P500 52-Week Change 8.67%
52 Week High 186.12 USD
52 Week Low 122.14 USD
50-Day Moving Average 149.14 USD
200-Day Moving Average 149.38 USD

NBIX Share Statistics

Avg. Volume (3 month) 1.33M USD
Avg. Daily Volume (10-Days) 1.35M USD
Shares Outstanding 101.22M
Float 99.91M
Short Ratio 4.53
% Held by Insiders 1.07%
% Held by Institutions 105.33%
Shares Short 5.9M
Short % of Float 7.58%
Short % of Shares Outstanding 5.83%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 18.97%
Operating Margin (ttm) 26.62%
Gross Margin 64.67%
EBITDA Margin 28.88%

Management Effectiveness

Return on Assets (ttm) 12.45%
Return on Equity (ttm) 20.41%

Income Statement

Revenue (ttm) 3.7B USD
Revenue Per Share (ttm) 36.73 USD
Quarterly Revenue Growth (yoy) 41.19%
Gross Profit (ttm) 2.39B USD
EBITDA 1.07B USD
Net Income Avi to Common (ttm) 702.5M USD
Diluted EPS (ttm) 6.74
Quarterly Earnings Growth (yoy) -1.40%

Balance Sheet

Total Cash (mrq) 737.9M USD
Total Cash Per Share (mrq) 7.29 USD
Total Debt (mrq) 451.8M USD
Total Debt/Equity (mrq) 11.65 USD
Current Ratio (mrq) 2.04
Book Value Per Share (mrq) 38.289

Cash Flow Statement

Operating Cash Flow (ttm) 1.07B USD
Levered Free Cash Flow (ttm) 1.02B USD

Profile of Neurocrine Biosciences

Country United States
State CA
City San Diego
Address 6027 Edgewood Bend Court
ZIP 92130
Phone 858 617 7600
Website https://www.neurocrine.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 2500

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Q&A For Neurocrine Biosciences Stock

What is a current NBIX stock price?

Neurocrine Biosciences NBIX stock price today per share is 150.57 USD.

How to purchase Neurocrine Biosciences stock?

You can buy NBIX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Neurocrine Biosciences?

The stock symbol or ticker of Neurocrine Biosciences is NBIX.

Which industry does the Neurocrine Biosciences company belong to?

The Neurocrine Biosciences industry is Drug Manufacturers - Specialty & Generic.

How many shares does Neurocrine Biosciences have in circulation?

The max supply of Neurocrine Biosciences shares is 101.22M.

What is Neurocrine Biosciences Price to Earnings Ratio (PE Ratio)?

Neurocrine Biosciences PE Ratio is 22.33976400 now.

What was Neurocrine Biosciences earnings per share over the trailing 12 months (TTM)?

Neurocrine Biosciences EPS is 6.74 USD over the trailing 12 months.

Which sector does the Neurocrine Biosciences company belong to?

The Neurocrine Biosciences sector is Healthcare.

Neurocrine Biosciences NBIX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3815.19 USD —
-1.22
121.01M USD — 3805.63 USD — 3911.38 USD — — 121.01M USD —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7414.87 USD —
-1.68
— — 7398.95 USD — 7631.86 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2214.31 USD —
-0.8
— — 2209.33 USD — 2262.42 USD — — — —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Composite Total Return XCMP US 27958.09 USD —
-5.28
— — 27828.65 USD — 29466.09 USD — — — —
us US Tech Global Select Market Com NQGS US 11139.01 USD —
-5.31
— — 11086.73 USD — 11742.47 USD — — — —
us US Tech Next Generation 100 Inde NGX US 1607.36 USD —
-3.42
— — 1601.83 USD — 1668.4 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
$2.1T
Total marketcap
$156.78B
Total volume
BTC 58.01%   •   ETH 9.91%
Dominance
Select currency